Technical Roundup on Drugs - Generic Equities -- Allergan, Akorn, Ironwood Pharma, Pacira Pharma, and Catalent

Jul 21, 2015, 09:15 ET from www.equityresearchinstitute.com

NEW YORK, July 21, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: Allergan PLC (NYSE: AGN), Akorn Inc. (NASDAQ: AKRX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), and Catalent Inc. (NYSE: CTLT). Free research report on Allergan can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AGN On Monday, July 20, 2015, the NASDAQ Composite ended at 5,218.86, up 0.17%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 18,100.41, and the S&P 500 closed at 2,128.28, up 0.08%. The losses were broad based as five out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.  

On Monday, shares in Allergan PLC recorded a trading volume of 1.20 million shares, lower than their three months average volume of 2.09 million shares. The stock ended the day 0.49% higher at $317.75. Allergan PLC's stock has advanced 5.05% in the last one month, 7.58% in the previous three months and 23.44% on YTD basis. The company is trading above its 50-day and 200-day moving averages by 4.52% and 13.65%, respectively. Furthermore, shares of Allergan PLC have a Relative Strength Index (RSI) of 60.87. Sign up and read the free notes on AGN at:

https://www.EquityResearchInstitute.com/reports?keyword=AGN

Akorn Inc.'s stock lost 1.36%, to close Monday's session at $44.92. The stock recorded a trading volume of 0.72 million shares, below its three months average volume of 1.94 million shares. Over the last one month and the previous three months, Akorn Inc.'s shares have declined 6.90% and 17.82%, respectively. However, the stock has surged 24.09% since the start of this year. The company is trading 1.30% and 3.55% above its 50-day and 200-day moving averages, respectively. Furthermore, Akorn Inc.'s stock traded at a PE ratio of 140.37 and has an RSI of 53.05. The complimentary notes on AKRX can be downloaded in PDF format at:

https://www.EquityResearchInstitute.com/reports?keyword=AKRX

Ironwood Pharmaceuticals Inc.'s stock finished Monday's session 1.06% lower at $11.18. A total of 1.72 million shares were traded, which was above its three months average volume of 1.35 million shares. Over the last one month and the previous three months, Ironwood Pharmaceuticals Inc.'s shares have lost 6.83% and 26.93%, respectively. Additionally, the stock has declined 27.02% since the beginning of 2015. The company's shares are trading below their 50-day and 200-day moving averages by 12.79% and 21.41%, respectively. Ironwood Pharmaceuticals Inc.'s stock has an RSI of 32.06. Register for free on Equity Research Institute and access the latest research on IRWD at:

https://www.EquityResearchInstitute.com/reports?keyword=IRWD

On Monday, shares in Pacira Pharmaceuticals Inc. ended the session 2.72% higher at $63.44. The stock reported a trading volume of 0.89 million shares, above its three months average volume of 0.79 million shares. Pacira Pharmaceuticals Inc.'s shares have plummeted 18.85% in the last one month, 24.66% in the previous three months and 28.45% on YTD basis. The company is trading 14.53% below its 50-day moving average and 29.55% below its 200-day moving average. Moreover, shares of Pacira Pharmaceuticals Inc. have an RSI of 31.48. The complete research on PCRX is available for free at:

https://www.EquityResearchInstitute.com/reports?keyword=PCRX

Catalent Inc.'s stock declined 1.34%, to close the day at $29.41. The stock recorded a trading volume of 0.55 million shares, below its three months average volume of 0.73 million shares. Over the last one month and over the past three months, Catalent Inc.'s shares have lost 4.17% and 5.10%, respectively. However, the stock has advanced 5.49% since the start of this year. The company's shares are trading 3.32% above their 200-day moving average. Additionally, Catalent Inc. traded at a PE ratio of 37.23 and has an RSI of 44.32. Free in-depth research on CTLT is available at:

https://www.EquityResearchInstitute.com/reports?keyword=CTLT

--

About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.equityresearchinstitute.com.

RESTRICTIONS 

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.equityresearchinstitute.com